FIELD: diagnostics.
SUBSTANCE: invention relates to diagnostics, namely to a method for determining the functional activity of the classical pathway of the human complement system for predicting the severity of the course of the systemic inflammatory response. A method for determining the functional activity of the classical pathway of the human complement system for predicting the severity of the course of a systemic inflammatory reaction includes carrying out a lysis reaction of human erythrocytes of group A of the AB0 system (E(A)), sensitized with anti-A monoclonal IgM antibodies (E(A)mAb) and serum under conditions of veronal saline buffer (VBS2+), incubation of the obtained sample, then the reaction of complement-dependent lysis of E(A)mAb is evaluated turbidimetrically, by reducing the optical density of the suspension E(A)mAb at a wavelength of 620 nm determines the degree of erythrocyte lysis in experimental samples according to the calibration graph, where the control E(A)mAb represents 0% lysis, and the control of complete lysis E(A)mAb is 100% lysis, under certain conditions, while the increased functional activity of the classical pathway of the human complement system is noted with a degree of lysis of more than 60%, with a degree lysis from 31% to 59% as normal and with a degree of lysis less than 30% as reduced functional activity of the human complement system.
EFFECT: above-described method allows increasing the accuracy of the method for studying the functional activity of the classical pathway of the complement system, as well as to simplify the registration of the results of the analysis of the functional activity of the classical pathway of the complement system in routine studies and adaptation of the method for screening studies in the conditions of clinical diagnostic laboratories.
1 cl, 5 dwg, 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETERMINING COMPLEMENT-ACTIVATING FUNCTION OF SARS-CoV-2 ANTIBODIES FOR PREDICTING SEVERITY OF COVID-19 | 2023 |
|
RU2818351C1 |
METHOD OF PREDICTING SEVERITY OF SYSTEMIC INFLAMMATORY RESPONSE IN HUMAN BODY IN DISEASES | 2022 |
|
RU2808416C1 |
METHOD FOR DETERMINING THE INHIBITORY POTENTIAL OF BLOOD FOR PREDICTING UNCONTROLLED ACTIVATION OF COMPLEMENT SYSTEM IN COVID-19 | 2023 |
|
RU2814496C1 |
SCREENING TEST FOR DETERMINATION OF THE FUNCTIONAL ACTIVITY OF THE RAT COMPLEMENT SYSTEM | 2022 |
|
RU2786208C1 |
SCREENING TEST FOR DETERMINING THE FUNCTIONAL ACTIVITY OF THE CLASSIC COMPLEMENT PATHWAY | 2018 |
|
RU2704121C1 |
METHOD OF DETERMINING THE ACTIVITY OF THE CLASSICAL AND ALTERNATIVE PATHWAYS OF THE MOUSE COMPLEMENT SYSTEM | 2022 |
|
RU2800363C1 |
METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19 WITH THE USE OF PEPTIDE IMMUNOGENS | 2020 |
|
RU2743593C1 |
PEPTIDE IMMUNOGENS USED AS COMPONENTS OF VACCINE COMPOSITION AGAINST COVID-19 | 2020 |
|
RU2743594C1 |
Authors
Dates
2021-10-05—Published
2021-06-09—Filed